Evidence map›Paper›PMID 39487951›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

MRI-based radiogenomics analysis for predicting prognosis and XRCC1 gene polymorphism in pancreatic ductal adenocarcinoma.

Muhammet Göktaş, Derya Karabulut, Ayhan Ünlü, Gkioulsoum Achmet, Nermin Tunçbilek

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Muhammet GöktaşDepartment of Radiology, Trakya University, Edirne, Turkey. muhammet_gokts@hotmail.com.ORCID http://orcid.org/0000-0003-1895-8789
Derya KarabulutDepartment of Radiology, Trakya University, Edirne, Turkey.
Ayhan ÜnlüDepartment of Biophysics, Trakya University, Edirne, Turkey.
Gkioulsoum AchmetDepartment of Biophysics, Trakya University, Edirne, Turkey.
Nermin TunçbilekDepartment of Radiology, Trakya University, Edirne, Turkey.

Funding

Trakya Üniversitesi 2020/81
6 · The paper itself

Abstract

purposeTo evaluate the prognostic effects of apparent diffusion coefficient (ADC) values, qualitative MRI findings, and XRCC1 polymorphism in patients with pancreatic ductal adenocarcinoma (PDAC).

methodsBetween January 2019 and December 2021, 41 PDAC patients (23 males; 66.6 ± 8.9 years) diagnosed with MRI and treated with chemotherapy were included in this prospective, unicenter study. Quantitative b:0-800 ADC values were calculated at the workstation using a circular region of interest with a diameter of 2 cm

resultsThe median overall survival time was calculated as 9.27 ± 1.4 months. The cut-off value of ADCmin was found to be 0.996 × 10

conclusionsADCmin values are useful for predicting prognosis in patients with PDAC. XRCC1 gene polymorphism may affect the age at diagnosis.

Indexed as

Carcinoma, Pancreatic DuctalMagnetic Resonance ImagingPancreatic NeoplasmsX-ray Repair Cross Complementing Protein 1AgedDiffusion Magnetic Resonance ImagingFemaleGenotypeHumansMaleMiddle AgedPolymorphism, GeneticPrognosisProspective StudiesX-ray Repair Cross Complementing Protein 1XRCC1 protein, humanApparent diffusion coefficientMagnetic resonance imagingPancreatic ductal adenocarcinomaRadiogenomicsXRCC1 polymorphism

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.